When a CUSABIO reagent travels across borders to reach a laboratory, it represents more than a protein or an antibody—it supports a scientific hypothesis awaiting validation.
When data generated using CUSABIO products are successfully reproduced, they confirm more than experimental results—they reflect a shared global commitment to precision, reliability, and rigor.
When research citing CUSABIO is published in leading scientific journals, it signifies more than discovery. It reflects a long-standing partnership between researchers and a brand built on trust, consistency, and progress.
This trust is central to everything we do—and to the meaning behind the name CUSABIO: Customer Satisfied Biological Reagents.
Product Innovation
Evolving with Scientific Needs
In 2025, product development at CUSABIO continued to be guided by real-world research needs. We believe that effective research tools should enable scientific thinking—not limit it.
Our full-length transmembrane protein library expanded to over 700 targets, spanning 15 key research areas, from oncology and immunology to neuroscience. This portfolio includes high-interest drug targets such as CLDN18.2, CLDN6, CD20 (MS4A1), and SLC2A1. Many of these proteins were previously difficult to express and purify; today, they are available through stable and reproducible supply.
Our recombinant antibody portfolio grew to over 2,000 products, including 200+ research-grade biosimilar antibodies. Covering immune checkpoints, oncogenic drivers, and neural markers, these antibodies can be used directly as positive controls in drug discovery or for rapid biological validation of target proteins.
In response to limited sample availability, CUSABIO introduced mini-sample ELISA kits. These kits deliver sensitivity, specificity, and precision comparable to—or exceeding—traditional 100 μL assays, while reducing sample volume requirements by up to 75%. This enables sustained research using precious materials such as transgenic animal samples, clinical aspirates, and pediatric specimens.
By the end of 2025, the CUSABIO product ecosystem included:
- 16,000+ recombinant proteins
- 70,000+ antibodies
- 3,000+ ELISA kits
Each new product reflects our anticipation of emerging research trends and our active response to customer feedback.
Integrated Solutions
From Individual Tools to End-to-End Support
Modern biopharmaceutical research requires integrated, workflow-based support. In 2025, CUSABIO further strengthened its three core solution platforms, forming a comprehensive support network across the full drug development lifecycle.
ADC Drug Development Solutions
CUSABIO's ADC solutions now support early discovery, preclinical, and clinical research stages. Based on project needs, we provide targeted products and services across key phases including target selection, antibody discovery and optimization, quality control, and clinical studies.
Cell Therapy Solutions
In the field of cell therapy, CUSABIO introduced SPR analysis services and HCP detection ELISA kits, further expanding our solution portfolio. Together, these offerings support: therapeutic molecule design and validation, multidimensional in vitro immune cell evaluation, process development and quality control, preclinical and translational research.
To further accelerate discovery, we enhanced our antibody discovery platforms, including hybridoma, single B cell, and VHH nanobody technologies, supported by AI-assisted workflows. In 2025, we successfully delivered 200+ therapeutic antibodies, providing end-to-end services from antigen preparation and antibody screening to cell line development and large-scale production—with a 100% delivery success rate.
Mouse hybridoma screening
Traditional method for high-specificity antibodies
Single B cell sorting
High-throughput screening for monoclonal antibodies
VHH library screening
Ideal for nanobody development
Service Excellence
Partnership Beyond Product Delivery
At CUSABIO, service extends beyond delivery. We work as long-term partners, sharing both challenges and responsibilities throughout the research process.
Our "No Protein, No Charge" custom protein program was comprehensively upgraded in 2025, achieving a customer satisfaction rate of 99.1%. This model reflects our belief that scientific uncertainty should not be borne by researchers alone.
Global Engagement
Connecting the Scientific Community
Science advances through collaboration. In 2025, CUSABIO continued to serve as a platform for global scientific exchange.
Throughout the year, we participated in 24 international academic conferences and industry exhibitions, spanning 15 major biopharmaceutical hubs across North America, Europe, and the Asia-Pacific region. In cities including Boston, Chicago, Billerica, Lisbon, etc. CUSABIO engaged with tens of thousands of researchers and industry professionals.
Our CUSABIO Lecture Series released 25 technical seminars, covering topics such as single B cell technologies, DT3C, and transmembrane proteins, as well as practical guidance on ELISA sample processing and data analysis. Across platforms, total viewership exceeded 100,000.
Scientific Impact
Recognition Through Contribution
In 2025, more than 29,000 SCI publications cited CUSABIO products, with a cumulative impact factor exceeding 100,000. Research supported by CUSABIO appeared in leading journals such as Cell, Nature, Signal Transduction and Targeted Therapy, and Cell Metabolism, addressing critical challenges in cancer immunotherapy, neurodegenerative diseases, metabolic disorders, and other frontier fields.
Looking Ahead
Continuing the Journey of Discovery
Looking back on 2025, we recognize the late-night experiments, the first appearance of promising data, and the moment a manuscript is accepted. These defining milestones—created by researchers worldwide—are closely connected to CUSABIO through the tools that supported them.
Many transformative scientific questions emerge from sustained experimental work. CUSABIO’s role is to ensure researchers have reliable, reproducible tools when results matter most.
Moving into 2026, CUSABIO will continue to align product development with emerging scientific needs. Customer Satisfied Biological Reagents is not a static slogan—it is a commitment renewed through every product iteration, service improvement, and scientific exchange.
Our brand promise remains unchanged, while our understanding of “satisfaction” continues to evolve alongside scientific progress. This is the future CUSABIO is building—together with the global research community.
Customer Satisfied Biological Reagents
CUSABIO — Built on Trust. Driven by Science.
CUSABIO team. Across Borders, Built on Trust. CUSABIO 2025 Year-in-Review. https://www.cusabio.com/c-21287.html
